27
Participants
Start Date
December 31, 2010
Primary Completion Date
July 31, 2012
Study Completion Date
July 31, 2012
Ruxolitinib
"Phase I - Starting dose of 50 mg by mouth twice a day for 28 day cycle.~Phase II - MTD reached in Phase I."
University of Texas MD Anderson Cancer Center, Houston
Collaborators (1)
Incyte Corporation
INDUSTRY
M.D. Anderson Cancer Center
OTHER